arxiv
PublishedMay 8, 2026 at 4:00 AM
▲bullish
Optimizing Social Utility in Sequential Experiments
Publisher summary· verbatim
arXiv:2605.06520v1 Announce Type: cross Abstract: Regulatory approval of products in high-stakes domains such as drug development requires statistical evidence of safety and efficacy through large-scale randomized controlled trials. However, the high financial cost of these trials may deter develope
Stay posted· Newsletter
Three short emails a week: Monday, Wednesday and Friday. Top movers, new models and the most-referenced story.
Your email is used only to send The Bubble Brief. Privacy policy
Discussion
No replies yet. Be first.
Related coverage
The Bubble Brief
MON · WED · FRIRead regulatory-approval insights every Monday, Wednesday and Friday — top movers, new models, story of the week.
Your email is used only to send The Bubble Brief. Privacy policy
Originally published on arxiv ↗